A causal role has been inferred for ERBB2 overexpression in the etiology of breast cancer and other epithelial malignancies. The development of therapeutics that inhibit this tyrosine kinase cell surface receptor remains a high priority. This report describes the specific downregulation of ERBB2 protein and mRNA in the breast cancer cell line SK-BR-3 by using antisense DNA phosphorothioates. An approach was developed to examine antisense effects which allows simultaneous measurements ofantisense dose and gene specific regulation on a per cell basis. A fluorescein isothiocyanate end-labeled tracer oligonucleotide was codelivered with antisense DNA followed by immunofluorescent staining for ERBB2 protein expression. Two-color flow cytometry measured the amount of both intracellular oligonucleotide and ERBB2 protein. In addition, populations of cells that received various doses of nucleic acids were physically separated and studied. In any given transfection, a 100-fold variation in oligonucleotide dosage was found. ERBB2 protein expression was reduced greater than 50%1, but only in cells within a relatively narrow uptake range. Steady-state ERBB2 mRNA levels were selectively diminished, indicating a specific antisense-effect. Cells receiving the optimal antisense dose were sorted and analyzed for cell cycle changes. After 2 days of ERBB2 suppression, breast cancer cells showed an accumulation in the G1 phase of the cell cycle.
events in the progression of breast cancer, and these properties are maintained during metastatic spread of the disease (6, 7) . The oncogenic capacity of ERBB2 can be directly demonstrated by introducing high-level expression vectors into nontransformed fibroblasts, mammary epithelial cells, and transgenic mice, which results in morphologic and growth changes characteristic of neoplasia (8) (9) (10) . In addition, ERBB2 has a relatively restricted pattern of expression in normal adult tissues (11) . These properties make the ERBB2 gene and protein product appealing targets for immune and gene-based therapies for breast cancer.
Decreased expression of ERBB2 has been achieved by using monoclonal antibodies specific for the extracellular domain of the protein (12) (13) (14) . This has resulted in growth inhibition and, in some cases, differentiation of breast cancer cell lines. Antibodies have been shown to decrease cell surface expression of the ERBB2 receptor via internalization (15) . These antibodies may also be acting as receptor agonists, mimicking ligand binding. Ligands for ERBB3 and ERBB4 have similar differentiating effects on breast epithelial cell lines (16) (17) (18) (19) (20) .
Antibody treatment can be equally effective on cell lines with both normal and high level ERBB2 expression (14) , further obscuring the target specificity and mechanism of this approach.
Intracellular delivery of antisense or antigene oligonucleotides has the ability to downregulate the expression of specific genes. Unmodified phosphodiester (PO) oligomers have been used successfully to modulate expression of certain genes in tissue culture cells; however, their nuclease susceptibility makes them an unlikely candidate for therapeutic use (21, 22) . Phosphorothioate (PS) oligomers are much more nuclease resistant, contain the same charge density as PO oligomers, and are relatively easy to synthesize. Despite the longer half-life in serum and in cells, PS oligomers in many cases have been ineffective in specifically downregulating mammalian target genes (21) . Effects are sometimes seen with both antisense and control compounds, or no effect is observed. Nonspecific toxicity of the thioate DNAs and poor cellular entry or bioavailability are the most likely explanations for these results. Therefore, when initially demonstrating an antisense effect, it is becoming common practice to bypass the cell membrane and deposit the compound into the cytoplasm via microinjection or through the use of cationic liposomes (23) (24) (25) . PS oligomers in the cytoplasm quickly accumulate in the nucleus (26) (27) (28) . Although high nuclear concentrations of the oligomers can be achieved, sorting out specific antisensemediated effects is still problematic.
We report here the specific downregulation of ERBB2 mRNA and protein by antisense PS oligonucleotides. These results were obtained via a flow cytometric approach capable of simultaneously monitoring the intracellular accumulation of oligonucleotides, gene expression, and cell cycle events. Using this technique, we found that optimal modulation of ERBB2 expression was achieved over a relatively narrow dosage range of PS oligomer and that this downregulation resulted in accumulation of cells in the G1 phase of the cell cycle.
MATERIALS AND METHODS
Oligonucleotides. Antisense and scrambled control PS oligonucleotides were synthesized on an ABI 380B DNA synthesizer (Perkin-Elmer). After synthesis, oligomers were purified by HPLC and purity was ensured by collection of a single peak. 31P-NMR was then performed on all syntheses to verify that thio linkages were greater than 95% of the total. Oligonucleotides reported in this manuscript had the following sequences: US-1 (AUG antisense), CTCCATGGTGCTCAC; US-D (scrambled sequence control), CGCCTTATCCG-TAGC; intron acceptor, TCCACCAGCTGGGGT. 
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Cell Cycle Analysis. Cells were labeled with 1 ,uM BrdUrd for 40 min. Detection of BrdUrd incorporation was performed as described by Lowe et al. (30) except that 1 p.g of DAPI dye per ml was used to stain DNA instead of propidium iodide. A minimum of 10,000 events were collected for each cell cycle profile.
RESULTS
Uptake and Detection of Tracer Oligonucleotide. The human mammary carcinoma line SK-BR-3 exhibits 100-fold overexpression of the ERBB2 protein when compared with normal mammary epithelial cells (4 (Fig. 1 A and B, respectively) . No change in the ERBB2 levels either between the two sequences or compared with lipofection alone was detected at this early time point (1.5 h). Cotransfection of cells with the FITC-labeled tracer oligonucleotide at a 1:6 ratio with either US-1 (Fig. 1C) or US-D (Fig. 1D) (Fig. 3 B and C that were not sorted. The unsorted ("Total") population of antisense oligonucleotide-treated cells showed less than a 50% reduction of ERBB2 mRNA compared with the control sequence (Fig. 3A) . In contrast, the M2 (high FITC)-sorted population showed about a 95% reduction in ERBB2 mRNA, when samples were normalized for loading and compared with the scrambled control sequence. These results imply that downregulation is due to an antisense mechanism mediated by degradation of the target mRNA. The lag in protein downregulation compared with mRNA reduction is consistent with the long half-life of the ERBB2 protein (>12 hours; J.P.V., unpublished data). (Fig. 4) . Quantitation of ERBB2 protein in three different FITC windows (low, middle, and high) demonstrated the biphasic nature of the response. At 44 h, the mid-FITC window had a mean ERBB2 level that was 50% of control (US-D), compared with 86% for the high dosage. By 68 h, cells containing high levels of FITC were still at 60% of the control ERBB2 levels, compared with 38% for the middle dosage. While we observed greater ERBB2 downregulation in cells that maintain the oligonucleotide over time, the number of cells containing high levels of FITC-labeled oligonucleotide is also reduced with time. Loss of oligonucleotide at later time points is likely due to a combination of degradation, efflux, and cell doubling. At later time points (.96 h), there was a further reduction in mean levels of ERBB2; however, there were very few cells that maintained substantial amounts of oligomer. Results from a number of experiments of this type demonstrated that the greatest number of cells with maximal ERBB2 inhibition was found approximately 50 h after treatment. Again, this indicates that there is an optimal dosage of the antisense oligomer beyond which reduction in ERBB2 protein is diminished. The tight correlation of FITC levels and the amount of ERBB2 downregulation over time further support the conclusion that the FITC-labeled tracer is representative of the antisense oligomer dosage. ERBB2 Downregulation Is Accompanied by an Accumulation of Cells in G1. The power of this technique was demonstrated by the ability to analyze other parameters in subpopulations of cells that received varying doses of oligomers. With downregulation of the ERBB2 oncogene, we expected to find alterations in cell cycle distribution (32) . Cultures of SK-BR-3 cells were lipofected as above with either antisense or scrambled control DNA. At 50 h after lipofection, the cells were pulsed with BrdUrd for 40 min. The cells were then harvested and sorted into low and high (corresponding to maximal ERBB2 downregulation) FITC populations. A fraction of these cells were stained and analyzed for ERBB2 protein (Fig.  5 A and B shows the high FITC windows). Typical downregulation was observed in these sorted cells. Incorporated BrdUrd was detected in the remaining cells followed by DAPI staining (Fig. 5 C and D) . In this way, we could measure cell cycle effects in subpopulations of cells expressing different levels of ERBB2. The results of this analysis show that, compared to the US-D control sequence, the antisense oligomer resulted in a 30% increase in cells in G1 and a reduced number of cells in S and G2/M. This effect was highly reproducible with the AUG antisense sequence and the splice-acceptor sequence (data not shown). This cell cycle effect was at the limit of detection when unsorted populations of cells were analyzed.
DISCUSSION
In this report, we have shown specific downregulation of ERBB2 protein and mRNA by antisense DNA PS oligomers. The technique employed also allowed us to examine the dose-response profile of this downregulation and enabled the isolation of populations of cells that received specific intracellular doses. From these experiments, we conclude that the response to the PS antisense oligomer was biphasic, with a maximal downregulation achieved in the middle of the dosage range delivered by liposomes. We also demonstrated that inhibition of ERBB2 expression was associated with an accumulation of SK-BR-3 cells in the G1 phase of the cell cycle.
Liposome-mediated antisense oligonucleotide delivery has been used to assess the efficacy of both antisense sequences and oligomer modifications in downregulating target genes (23, 24, 28) . The conditions that were employed in our experiments were modeled after the work of Bennett et al. (23) who successfully targeted the ICAMI gene with antisense PS oligomers. Our addition of an FITC-labeled trace oligomer of the same length as the antisense (or control) compound revealed that on a per-cell basis, there is significant heterogeneity in the dosage of oligomers delivered by DOTMA liposomes. In SK-BR-3 cells, lipofection is 70-80% efficient, but per-cell doses ranged over 100-fold, as measured by fluorescent intensity. This heterogeneity and narrow optimal dose create an underestimate of the efficacy of antisense treatments.
Our experiments support previous contentions that only a narrow dosage range exists in which antisense PS oligomers exhibit specific downregulation. On the basis of studies of permeabilized rabbit reticulocytes, the antisense effect of PS oligomers has been shown to be biphasic. Nonspecific inhibition of translation occurs at concentrations above 1 ,uM (33) . This led to a prediction that these compounds would have a narrow window of maximal efficacy in cells (21) . Microinjection studies have also shown a nonspecific inhibition of translation at doses of approximately 20 ,uM (34) . Two things may be occurring at high doses: (i) Nonspecific inhibition of RNase H activity has been demonstrated at high concentrations of PS oligomers in reconstitution studies (35) . At low concentrations, PS oligomers enhanced RNase H cleavage of RNA-DNA hybrids, while at oligomer concentrations exceeding the target RNA, the oligomers could protect the RNA from degradation.
(ii) Nonspecific inhibition of protein synthesis may result in a decrease in protein turnover. Toxic levels of PS oligomer may shut down normal cellular processes, including receptor internalization and replacement. From our Northern blot data, it appeared that ERBB2 mRNA is efficiently inhibited over a broad dosage range, suggesting that the retention of ERBB2 protein in cells containing the highest levels of oligomer is more likely due to nonspecific inhibition of protein turnover rather than a loss of RNase H activity.
The rationale for performing these experiments was to explore the biologic consequences of downregulating ERBB2 in breast cancer cells that overexpress this oncogene. The subpopulation of cells that were optimally downregulated for ERBB2 demonstrated a shift in the cell cycle profile indicative of an increased time or arrest in the G1 phase. Previous studies modulating the ERBB2 receptor by anti-ERBB2 antibodies resulted in marked growth inhibition (arrest in G2) and differentiation into secretory cells (32) . While a reduction in growth was noted in our antisense experiments, the cells accumulated in the G1 phase, and we did not detect accumulation of lipid droplets characteristic of secretory differentiation (data not shown). In light of the properties of ligands (heregulin/neu differentiation factor) influencing ERBB2 (16, 20) , it is likely that the antiproliferative antibodies against ERBB2 exerted their effects by acting as receptor agonists. While decreasing the levels ofERBB2 mRNA and protein does not completely inhibit entry of SK-BR-3 cells into S phase, other parameters, such as growth in vivo and in semi-solid media, may be more dramatically affected. Our ability to sort populations after lipofection allows us to test these and other possibilities directly.
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